ReviewNeuro-oncology advances
Outcomes of target therapies for pediatric BRAF V600-mutant low-grade gliomas: A systematic review and meta-analysis.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This systematic review and meta-analysis evaluated the efficacy, safety, and available functional outcomes of targeted therapies, including BRAF and MEK inhibitors, in pediatric patients with BRAF V600-mutant low-grade gliomas (pLGGs). The review also explored their impact on clinical management, recovery, and quality of life. Methods: The review followed PRISMA 2020 guidelines. Systematic searches were conducted across PubMed, ScienceDirect, EBSCO-hosted databases, and CENTRAL. Eligible studies included randomized controlled trials (RCTs) and retrospective studies (RS) reporting on tumor overall response rates (ORRs), progression-free survival (PFS), adverse events (AEs), and functional outcomes in patients aged 1-17 years. Risk of bias was assessed using CASP; the certainty of evidence was evaluated using the GRADE framework. Meta-analyses used a random-effects model (STATA 18.5). Funnel plots, Egger's tests, and subgroup/sensitivity analyses explored bias and heterogeneity. Results: Ten studies (16 treatment arms; 4 RCTs, 6 RS were included). Pooled ORR was 42.35% (95% CI, 29.41-55.29), and the median PFS was 23.03 months (95% CI, 17.18-28.88). Grade 3/4 AEs occurred in 30.56% (95% CI, 22.60-38.53), most commonly rash, fatigue, and fever. Subgroup analyses suggested higher efficacy and lower toxicity with BRAF inhibitors or combination therapy. Functional outcomes were inconsistently reported, though some evidence suggested improvements in vision and performance status. Conclusions: Targeted therapies are effective and well tolerated in pediatric BRAF V600-mutant LGG, offering a promising alternative to chemotherapy, particularly in relapsed or progressive disease. Emerging evidence suggests potential benefit in selected molecularly defined patients; however, further prospective studies are required to define their role in first-line treatment. Standardized outcome reporting and long-term follow-up are essential to optimize care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.